Bhattacharyya Neil
Division of Otolaryngology, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA.
Ann Otol Rhinol Laryngol. 2009 Mar;118(3):185-9. doi: 10.1177/000348940911800305.
This study was undertaken to determine the differential disease burden between chronic rhinosinusitis (CRS) cases with and without nasal polyposis (NP).
A consecutive series of adult patients who met clinical and radiographic criteria for CRS was assessed with the Rhinosinusitis Symptom Inventory, nasal endoscopy, and computed tomography. Three clinical groups were examined: 1) CRS without NP, 2) CRS with primary NP (no prior surgery), and 3) CRS with recurrent NP (prior surgery). The groups were compared with respect to symptom presentation, medical resource utilization, and medication costs.
Two hundred eighty-six CRS cases without NP, 131 CRS cases with primary NP, and 45 CRS cases with recurrent NP were studied; their mean Lund scores were 8.8, 13.2, and 16.3, respectively (p < 0.001). Statistically significant differences in severity for nasal (p = 0.002), facial (p = 0.025), oropharyngeal (p = 0.017), and systemic symptoms (p = 0.042) between groups were noted, whereas total symptoms did not differ between groups (p = 0.339). Medication use and physician visits were similar between groups (p = 0.335 and p = 0.951, respectively). The aggregate yearly medication costs were significantly greater for the recurrent polyp group ($866) than for either the non-polyp group ($570; p = 0.013) or the primary polyp group ($565; p = 0.020).
Patients with non-polyp CRS and those with primary polyp CRS present with different symptom phenotypes, but exhibit similar total symptom burdens and medical resource consumption. The presence of polyps does not necessarily confer a dramatic additional disease burden in CRS.
本研究旨在确定伴有和不伴有鼻息肉(NP)的慢性鼻-鼻窦炎(CRS)病例之间的疾病负担差异。
对一系列符合CRS临床和影像学标准的成年患者进行了鼻窦炎症状量表、鼻内镜检查和计算机断层扫描评估。研究了三个临床组:1)无NP的CRS,2)原发性NP(未接受过手术)的CRS,3)复发性NP(接受过手术)的CRS。比较了各组在症状表现、医疗资源利用和药物成本方面的情况。
研究了286例无NP的CRS病例、131例原发性NP的CRS病例和45例复发性NP的CRS病例;它们的平均Lund评分分别为8.8、13.2和16.3(p<0.001)。注意到各组之间在鼻部(p=0.002)、面部(p=0.025)、口咽部(p=0.017)和全身症状(p=0.042)的严重程度上存在统计学显著差异,而各组之间的总症状无差异(p=0.339)。各组之间的药物使用和医生就诊情况相似(分别为p=0.335和p=0.951)。复发性息肉组的年度药物总成本(866美元)显著高于无息肉组(570美元;p=0.013)或原发性息肉组(565美元;p=0.020)。
无息肉CRS患者和原发性息肉CRS患者表现出不同的症状表型,但总症状负担和医疗资源消耗相似。息肉的存在不一定会在CRS中带来显著的额外疾病负担。